A meta-analysis published in Circulation focused on the effects of SGLT2 inhibitors on adverse cardiovascular events in diabetes, heart failure, and chronic kidney disease patients. SGLT2 inhibitors reduced the rate of major cardiovascular events by 9%, primarily decreasing cardiovascular death, especially heart failure and sudden cardiac death. The study included 11 trials with 78,607 participants and found consistent effects across all patient populations. MACE risk reduction was observed regardless of ASCVD, diabetes, or kidney function status. SGLT2 inhibitors showed promise in reducing risk across cardiovascular, kidney, and metabolic disease spectrums, aiding in therapeutic decisions.
Source link
A game-changer in preventing heart failure and sudden cardiac deaths
